Summary
Capitainer AB aims to develop a business plan for the broad-scale commercial launch of Capitainer-B – an innovative tool for quantitative blood microsampling. For kidney transplant patients, a new organ eliminates the need of frequent dialysis and improves the quality of life, but to prevent rejection of the new organ by the patient’s own immune system, lifelong treatment with immunosuppressive drugs is necessary. To ensure that the concentration of drugs remain within their therapeutic windows, drug levels are continuously measured through blood testing after transplantation: TDM - Therapeutic Drug Monitoring. Traditional phlebotomy at the hospital consumes substantial resources from the healthcare system and for patients, frequent visits to the hospital/test station is a source of inconvenience. As such, the development of an accurate “use-at-home” blood sampling tool that can alleviate this heavy burden is in great demand. Filling this market gap, Capitainer AB proposes Capitainer-B - a portable, cost effective and easy-to-use microsampling system which enables the patient to take a blood sample at home through a finger prick. The sample can be sent via regular mail to the laboratory for analysis. Our design philosophy was to create a reliable and easy to use tool for monitoring drug concentrations in blood, thereby reducing the risk of organ refusal. From the business perspective, Capitainer-B expands into the market space delineated by the variables of volume accuracy, patient proximity, mobility and low cost. The device has already attracted attention of one EU-based medical centre in Germany (Labor Dessau GmbH) which resulted in a research partnership and low scale sales. In this Phase 1 Project, Capitainer AB intends to prepare a multispectral market feasibility assessment for Capitainer-B. Furthermore, we plan to study the market capacity for the further Capitainer-B-type devices, aiming at providing a comprehensive blood testing platform.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/868807 |
| Start date: | 01-05-2019 |
| End date: | 31-10-2019 |
| Total budget - Public funding: | 71 429,00 Euro - 50 000,00 Euro |
Cordis data
Original description
Capitainer AB aims to develop a business plan for the broad-scale commercial launch of Capitainer-B – an innovative tool for quantitative blood microsampling. For kidney transplant patients, a new organ eliminates the need of frequent dialysis and improves the quality of life, but to prevent rejection of the new organ by the patient’s own immune system, lifelong treatment with immunosuppressive drugs is necessary. To ensure that the concentration of drugs remain within their therapeutic windows, drug levels are continuously measured through blood testing after transplantation: TDM - Therapeutic Drug Monitoring. Traditional phlebotomy at the hospital consumes substantial resources from the healthcare system and for patients, frequent visits to the hospital/test station is a source of inconvenience. As such, the development of an accurate “use-at-home” blood sampling tool that can alleviate this heavy burden is in great demand. Filling this market gap, Capitainer AB proposes Capitainer-B - a portable, cost effective and easy-to-use microsampling system which enables the patient to take a blood sample at home through a finger prick. The sample can be sent via regular mail to the laboratory for analysis. Our design philosophy was to create a reliable and easy to use tool for monitoring drug concentrations in blood, thereby reducing the risk of organ refusal. From the business perspective, Capitainer-B expands into the market space delineated by the variables of volume accuracy, patient proximity, mobility and low cost. The device has already attracted attention of one EU-based medical centre in Germany (Labor Dessau GmbH) which resulted in a research partnership and low scale sales. In this Phase 1 Project, Capitainer AB intends to prepare a multispectral market feasibility assessment for Capitainer-B. Furthermore, we plan to study the market capacity for the further Capitainer-B-type devices, aiming at providing a comprehensive blood testing platform.Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
